Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial — Piero Ruggenenti (2019) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial
Shared by
Giuseppe Remuzzi
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial
Article
2019
en
Authors
+75 more
PR
Piero Ruggenenti
ED
Erica Daina
AG
Alessia Gennarini
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2020
Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation
Camillo Carrara
,
Manuel Alfredo Podestà
,
Mauro Abbate
,
Paola Rizzo
,
Rossella Piras
,
Marta Alberti
,
Erica Daina
,
Piero Ruggenenti
,
Giuseppe Remuzzi
Article
2013
Prevalence of C3 mutations in primary membranoproliferative glomerulonephritis
Elisabetta Valoti
,
Elena Bresin
,
Rossella Piras
,
Marta Alberti
,
Annalisa Sorosina
,
Roberta Donadelli
,
Giuseppe Remuzzi
,
Marina Noris
Article
2011
Clinical Patterns of Acute Poststreptococcal Glomerulonephritis: A Single Center's Experience
Rita Yu
,
Se-Jin Park
,
Jae Il Shin
,
Kee Hyuck Kim
Article
2025
Single-Arm Trials Can Provide Randomized Real-World Evidence: The Random Invitation Single-Arm Trial Design
Perrine Janiaud
,
John P A Ioannidis
,
Benjamin Kasenda
,
Atle Fretheim
,
Steven N. Goodman
,
Lars G. Hemkens
Article
2018
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
Marina Noris
,
Roberta Donadelli
,
Giuseppe Remuzzi
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.